Clinical trials: Glioma, Malignant
EphA2 Positive Malignant Glioma, CAR-T Cell Immunotherapy
CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients
The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in treating with EphA2 positive malignant glioma patients.
- Trial name
- NCT02575261
- Testing
- CAR-T cell immunotherapy
- Where
- China
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Brain and Central Nervous System Tumors
Temozolomide in Treating Patients With Recurrent Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who have recurrent…
- Trial name
- NCT00004113
- Testing
- temozolomide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Diagnoses Disease, Glioma of Brain
The Efficacy of APT Magnetic Resonance Imaging in Predicting the Efficacy of Bevacizumab in Recurrent Malignant Gliomas
Targeted therapy with bevacizumab is the main method to prolong the progression-free survival of patients with recurrent malignant gliomas in recent years.
- Trial name
- APT (NCT03180697)
- Testing
- APT MR Imaging
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhujiang Hospital
Glioma
ONC201 in Adults With Recurrent H3 K27M-mutant Glioma
This was a Phase 2, open-label, 2-arm study of dordaviprone (ONC201) in patients with recurrent H3 K27M- mutant glioma. The primary assessment of dordaviprone (ONC201) involved evaluating its anti-tumor activity through the…
- Trial name
- NCT03295396
- Testing
- Dordaviprone (ONC201)
- Where
- 9 sites in United States
- Volunteers
- 73 people
- Sponsor
- Jazz Pharmaceuticals
Brain Tumors
Fluorescence Guided Resection of Brain Tumors
Removing a tumor from your brain is hard to do because, very often, brain tumors do not have boundaries that are easy for your surgeon to find. In many cases, the surgeon can't tell exactly where the tumor begins or ends.
- Trial name
- FGR (NCT00870779)
- Testing
- 5-aminolevulinic acid
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- David W. Roberts
High Grade Glioma
Prospective Evaluation of T-cell Immune Status in Patients With Newly Diagnosed High Grade Gliomas
The primary goal of this study is evaluate T cell immune status and immune reconstitution and the association with specific cytokines in patients with newly diagnosed HGGs undergoing the standard RT/TMZ and adjuvant TMZ.
- Trial name
- NCT02041611
- Testing
- Blood collections
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Brain and Central Nervous System Tumors
TP-38 Toxin in Treating Young Patients With Recurrent or Progressive Supratentorial High-Grade Glioma
RATIONALE: The TP-38 toxin can locate tumor cells and kill them without harming normal cells. Giving TP-38 toxin directly into the tumor may kill more tumor cells.
- Trial name
- NCT00074334
- Testing
- TGFa-PE38 immunotoxin, conventional surgery
- Where
- 8 sites in United States
- Volunteers
- 3 people
- Sponsor
- Pediatric Brain Tumor Consortium
Brain and Central Nervous System Tumors
Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating adults with newly diagnosed…
- Trial name
- NCT00003464
- Testing
- temozolomide, radiation therapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Duke University
Recurrent Glioma, Glioma, Malignant
Role of Surgery in Treatment of Recurrent Brian Glioma:Prognostic Factors and Outcome
role of surgery in treatment of recurrent brain glioma prognostic factors and outcome measures Role of surgery : In patients with Grade I gliomas, such as pilocytic astrocytomas, resection is potentially curative.
- Trial name
- NCT04562077
- Where
- Egypt
- Volunteers
- 25 people
- Sponsor
- Assiut University
Glioma, Malignant
Multi-center Research Project for Glioma Molecular Pathology Intraoperative Rapid Detection
We explores the accuracy and sensitivity of rapid intraoperative detection of IDH, TERT, BRAF indicators through a prospective clinical multi-center study.
- Trial name
- NCT04904419
- Testing
- Intraoperative Rapid Detection mutation of IDH, TERT and BRAF v600e
- Where
- 4 sites in China
- Volunteers
- 137 people
- Sponsor
- Jinsong Wu
Newly Diagnosed Pediatric Pontine Glioma, Newly Diagnosed Pediatric High Grade Glioma
A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction with Poly-ICLC in Pediatric Gliomas
The overall objective of this pilot study is to collect immunological and safety data following administration of vaccinations with HLA-A2. This data will be used to decide whether a larger study of clinical efficacy is warranted.
- Conditions
- Newly Diagnosed Pediatric Pontine Glioma, Newly Diagnosed Pediatric High Grade Glioma, Recurrent Pediatric High Grade Glioma, Recurrent Pediatric Low Grade Glioma
- Trial name
- NCT01130077
- Testing
- HLA-A2 restricted glioma antigen peptides vaccine, Poly-ICLC
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- James Felker
Recurrent Malignant Glioma, Glioblastoma
Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas
GLIOTARG trial is a large single-center observational cohort study designed to investigate chemotherapy and targeted therapy outcomes in recurrent malignant gliomas.
- Conditions
- Recurrent Malignant Glioma, Glioblastoma, Anaplastic Astrocytoma, Pleomorphic Xanthoastrocytoma
- Trial name
- GLIOTARG (NCT07448480)
- Testing
- Bevacizumab-Containing Regimens, Non-Bevacizumab Regimens, BRAF ± MEK Targeted Therapy
- Where
- Russia
- Volunteers
- 1,000 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Glioma, Malignant
GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas
The purpose of this phase I trial is to test the safety of combining GMCI, an immunostimulator, plus nivolumab, an immune checkpoint inhibitor (ICI), with standard of care radiation therapy, and temozolomide in treating patients…
- Trial name
- GMCI (NCT03576612)
- Testing
- AdV-tk, Valacyclovir, Radiation
- Where
- 5 sites in United States
- Volunteers
- 41 people
- Sponsor
- Candel Therapeutics, Inc.
Glioma, Malignant, Ependymoma
In Vitro Models From Pediatric Brain Tumors
Tumors of the Central Nervous System (CNS) represent the leading cause of cancer-related deaths in children. Current treatment options are not curative for most malignant histologies, and intense preclinical and clinical research…
- Conditions
- Glioma, Malignant, Ependymoma, Medulloblastoma
- Trial name
- PBTS23 (NCT06499636)
- Testing
- other
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Malignant Glioma
Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme
This study is designed to evaluate the clinical activity of CDX-110 vaccination when given with standard of care treatment (maintenance temozolomide therapy).
- Trial name
- ACT III (NCT00458601)
- Testing
- CDX-110 with GM-CSF, Temozolomide
- Where
- 34 sites in United States
- Volunteers
- 82 people
- Sponsor
- Celldex Therapeutics
Glioma, Malignant
HSRT and IMRT Chemoradiotherapy for Newly Diagnosed GBM
This study aims to evaluate the safety and effectiveness of the combination of 30Gy/5fx HSRT and 20Gy/10fx IMRT adjuvant therapy.
- Trial name
- HSCK-010 (NCT04547621)
- Testing
- Radiation, Temozolomide
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Huashan Hospital
Malignant Gliomas, Glioblastoma Multiforme
The Safety and Efficacy of DCA for the Treatment of Brain Cancer
Malignant gliomas, which include Glioblastoma multiforme (GBM), are the most common and most aggressive types of brain cancer, accounting for approximately 60% of primary brain tumors.
- Trial name
- NCT00540176
- Testing
- Dichloroacetate (DCA)
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University of Alberta
Advanced Solid Tumors, Advanced Recurrent Ovarian Tumors
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
To determine the maximum tolerated dose or optimal biological dose, and the safety profile of MEDI3617 when given as a single-agent or in combination with other chemotherapeutic agents in subjects with advanced solid malignancies…
- Trial name
- NCT01248949
- Testing
- MEDI3617, Bevacizumab, Paclitaxel
- Where
- 10 sites in United States
- Volunteers
- 162 people
- Sponsor
- MedImmune LLC
Brain and Central Nervous System Tumors
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Brain Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation or bone marrow transplantation may allow the doctor to give higher doses…
- Trial name
- NCT00025558
- Testing
- filgrastim, carboplatin, temozolomide
- Where
- 4 sites in United States, Australia
- Sponsor
- NYU Langone Health
Brain Tumor Recurrent
Methotrexate and Etoposide Infusions Into the Fourth Ventricle in Children with Recurrent Posterior Fossa Brain Tumors
The goal of this clinical research study is to establish the safety of simultaneous infusions of methotrexate and etoposide into the fourth ventricle of the brain or resection cavity in patients with recurrent malignant posterior…
- Trial name
- NCT02905110
- Testing
- Methotrexate, Etoposide, Ommaya Reservoir
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- The University of Texas Health Science Center, Houston
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.